REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss

Key Takeaways Regeneron reported positive data from the CHORD study on its investigational gene therapy DB-OTO.DB-OTO improved hearing in 11 of 12 participants, with 3 achieving normal hearing levels.The therapy was well tolerated and met its primary endpoint; U.S. filings are planned later this year.Regeneron Pharmaceuticals, Inc. (REGN) announced updated data on its investigational gene therapy DB-OTO from the CHORD study.This gene therapy is being evaluated for profound genetic hearing loss due to varian ...